Navigation Links
Schering-Plough Announces European Submission of Fertility Medicine Corifollitropin Alfa
Date:12/31/2008

Corifollitropin alfa, a sustained follicle stimulant, extends options for patients and Schering-Plough's leadership in fertility

KENILWORTH, N.J., Dec. 31 /PRNewswire-FirstCall/ -- Schering-Plough Corp., (NYSE: SGP), a leading provider of fertility treatments, announced today that the European Medicines Agency (EMEA) has validated (accepted for review) its Marketing Authorization Application (MAA) for corifollitropin alfa, the company's experimental, sustained follicle stimulant (SFS). This application will follow the Centralized Procedure.

Corifollitropin alfa is being developed as a potential treatment in Controlled Ovarian Stimulation (COS) for the development of multiple follicles and pregnancy in women participating in an Assisted Reproductive Technology (ART) program. Corifollitropin alfa is designed as a sustained follicle stimulant with the same pharmacodynamic profile as (recombinant)Follicle Stimulating Hormone (FSH), but with a markedly prolonged duration of FSH activity. Due to its ability to initiate and sustain multiple follicular growth for an entire week, a single subcutaneous injection of the recommended dose of corifollitropin alfa may replace the first seven injections of (recombinant)FSH preparation in a COS treatment cycle.

If approved, corifollitropin alfa would extend Schering-Plough's leading fertility portfolio, which also includes PUREGON(R).

Corifollitropin alfa Important Safety Information

The most frequently reported adverse drug reactions during treatment with corifollitropin alfa in clinical trials are Ovarian Hyperstimulation Syndrome (OHSS), pelvic pain and discomfort, headache, nausea, fatigue and breast complaints (including tenderness). They are reported with an incidence between 1% and 6%.

PUREGON(R) Important Safety Information

<
'/>"/>
SOURCE Schering-Plough
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
2. Schering-Plough Schedules Conference Call and Webcast for 2007 Third Quarter Earnings
3. Schering-Plough Reports Financial Results for Third Quarter of 2007
4. Schering-Plough CEO Calls for Four-Pronged Approach to Improving Current Health Care Environment
5. Schering-Plough Reports U.S. District Court for District of Massachusetts Finds No Liability for Subsidiary in AWP Case
6. Schering-Plough to Webcast CFO Robert J. Bertolinis Presentation at 2007 Credit Suisse Health Care Conference
7. Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
8. Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock
9. Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab
10. Schering-Plough Board Elects Dr. Craig B. Thompson as a Director
11. Schering-Plough CEO to Buy $2 Million in Common Shares
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... 30, 2015 AVT, the world leader ... is joining forces with leading proofing solutions provider Global ... worldwide printing market. , Under the agreement, ... engine for its offline inspection solutions, which are customized ... and its varying production workflow setups and printing applications. ...
(Date:5/30/2015)... Thousands of aesthetic industry professionals converged in ... the American Society for Aesthetic Plastic Surgery (ASAPS). ... the parent company of one of the fastest expanding ... growth, the one-of-a-kind device just sold its 2 millionth ... in the news for gaining the FDA’s stamp of ...
(Date:5/30/2015)... One of the pervasive problems plaguing ... options available. Often, the ruralness of a location can ... rural areas feeling the crunch of a strained healthcare ... of paying high premiums and copays, Online USA ... physicians via the power of the internet. , ...
(Date:5/30/2015)... May 30, 2015 ProIntro Magnify contains 30 ... and animations. Instantly add an elegant opening title to any ... a range of clean design layouts. ProIntro Magnify is created ... is extremely easy to use. Simply drag a preset into ... on-screen-controls and parameters in the Inspector window then watch as ...
(Date:5/30/2015)... Minnesota (PRWEB) May 30, 2015 ... acquired the Disability Income Associate (DIA) designation to ... The DIA designation is designed for insurance advisors, ... to further their knowledge and expertise associated with ... Earning the DIA designation is only the latest ...
Breaking Medicine News(10 mins):Health News:AVT and Global Vision Collaborate to Offer Cutting-edge Offline Inspection Solutions for Printing Industry 2Health News:AVT and Global Vision Collaborate to Offer Cutting-edge Offline Inspection Solutions for Printing Industry 3Health News:Dr. Paul Vitenas Meets with Zeltiq President and CEO in Montreal 2Health News:Dr. Paul Vitenas Meets with Zeltiq President and CEO in Montreal 3Health News:Online USA Doctors Brings Healthcare to the Masses with New E-Consults 2Health News:Online USA Doctors Brings Healthcare to the Masses with New E-Consults 3Health News:Announcing the release of ProIntro Magnify from Pixel Film Studios. 2Health News:Secura Consultants Expands Disability Insurance Expertise 2
... Studies conducted on the health effects of tea and alcohol ... while the latter can increase the chances of committing a ... effects of green tea, which is claimed to have numerous ... leukemia patients who drank the beverage had an improved clinical ...
... smokers who suffer from withdrawal symptoms at the Queensland's public ... inpatients of all the // public hospitals in the country ... cost, from 1 January 2006. ,As many ... year. ,Nicotine is capable of creating blood ...
... study has indicated that the use of short wide glasses ... to 30% more. This has been published in the ... small glasses than in the narrow tall glasses of the ... by professional bartenders. ,The study involved 198 ...
... Report of the rising rates of infection with C.difficile ... the mutation of the microorganism into a more virulent ... only manifest in individuals with resistance to antibiotics. ... among non-hospitalized patients has created much panic among the ...
... Merck & Co, known as MSD India, has entered into ... to conduct studies on the former's investigational cervical cancer drug, ... development in India. Under the agreement, clinical trials will be ... cervical cancer. ,The vaccine that has been developed by ...
... has revealed that there is no evidence which proves that ... billion by way of lost wages as a result of ... the British Medical Journal recommends moderation while drinking to prevent ... based product, tropisetron, fructose, tolfenamic acid, artichoke, prickly pear, and ...
Cached Medicine News:Health News:Rising Rates Of C.Difficile Infection Among Non-Hospitalized Patients 2Health News:Merck, ICMR to conduct joint trials on cervical cancer vaccine 2
(Date:5/29/2015)... , May 28, 2015 Research and ... the "North America MRI Market - Growth, Trends ... offering. The North American MRI systems market ... in 2014 to $1.58 billion by 2020 with a ... are of three types namely, the open system, closed ...
(Date:5/29/2015)... N.J. , May 29, 2015 Actinobac ... companies originally funded with investments from Foundation Venture Capital ... at Bio International 2015 as part of the Start-Up ... announced FVCG President James M. Golubieski . ... the biotechnology industry, will be held in ...
(Date:5/29/2015)... Eli Lilly and Company (NYSE: LLY ... Healthcare Conference on Tuesday, June 9, 2015. Jeffrey ... Health, will participate in a fireside chat at 2:20 ... audio webcast will be available on the "Webcasts & ... . A replay of the fireside chat will be ...
Breaking Medicine Technology:North America MRI Market - Growth, Trends And Forecasts 2014-2019 with GE, Hitachi Medical, Philips Healthcare, Siemens Healthcare & Toshiba Medical Systems Dominating 2Foundation Venture Capital Group Portfolio Companies to be Highlighted at Bio International in June 2Foundation Venture Capital Group Portfolio Companies to be Highlighted at Bio International in June 3Lilly to Participate in Goldman Sachs Global Healthcare Conference 2
... PelviSoft® Acellular Collagen BioMesh, provides ... tissue together with the porosity of ... for use in pelvic floor reconstruction. ... and cystocele prolapse, where plication alone ...
... Allograft meets the demanding ... floor reconstructive procedures, and ... suture pull-through, demonstrating long-term ... a structural support for ...
The High Pure Viral RNA Kit is intended for general laboratory use and is designed to purify viral RNA from serum or plasma. Viral RNA is used for RT-PCR analysis directly after elution in nuclease-f...
... The QIAamp Viral RNA Mini ... nucleic acids from cell-free fluid ... acids that can be isolated ... are not limited to, RNA ...
Medicine Products: